Oral abstracts

ESVC – European Society of Veterinary Cardiology
Click here to read the speakers bio
Thursday 1 September
09.00-09.15 ESVC-O-1 Kurogochi Long-term results of mitral valve repair with artificial chordae and annuloplasty in small-breed dogs
09.15-09.30 ESVC-O-2 Menciotti Differences in mitral valve morphology between Cavalier King Charles Spaniels with mild mitral regurgitation and without mitral regurgitation. 
09.30-09.45 ESVC-O-3 Silva Analysis of pimobendan prescriptions in small breed dogs with myxomatous mitral valve disease using Electronic Health Records in Primary Care Veterinary Practices in the United Kingdom
09.45-10.00 ESVC-O-4 Pires Routine echocardiography in healthy senior cats. How reliable are left ventricular wall measurements?
10.00-10.15 ESVC-O-5 Colpitts Genes of inflammation and coagulation are activated in hearts from cats with hypertrophic cardiomyopathy
10.15-10.30 ESVC-O-6 den Toom Genome wide association study of congenital pulmonic stenosis in French Bulldogs 
11.20-11.35 ESVC-O-7 Franchini Agreement between different 2-D transthoracic views and 3-D transthoracic echocardiography in identifying mitral valve prolapse in dogs
11.35-11.50 ESVC-O-8 Dutton Aortic annular plane systolic excursion in cats with hypertrophic cardiomyopathy: 151 cases
11.50-12.05 ESVC-O-9 Zoia An overview on the inflammatory and systemic fibrinolysis status in cats with heart disease stratified by the presence and type of congestive heart failure
12.05-12.20 ESVC-O-10 Van Renterghem The impact of chronic right ventricular pressure overload on right and left heart morphology and function 
12.20-12.35 ESVC-O-11 Escalda Effects of angiographic contrast media on invasive pressure measurement in dogs with pulmonic stenosis undergoing balloon valvuloplasty.
12.35-12.50 ESVC-O-12 Mochel Breakthrough: A First-In-Class Virtual Simulator for Dose Optimization Of Angiotensin Converting Enzyme Inhibitors in Cardiology
Friday 2 September
09.45-10.00 ESVC-O-13 Langhorn Systemic hypocoagulability in cats with arterial thromboembolism detected by global hemostatic tests
10.00-10.15 ESVC-O-14 Schreiber Comparison of the diagnostic value of a small, single channel, electrocardiographic monitoring patch with a standard 3-lead Holter system over 24 hours in dogs
10.15-10.30 ESVC-O-15 Hezzell Genetic susceptibility of canine myxomatous mitral valve disease
11.20-11.35 ESVC-O-16 Victorino Machado Left atrial fractional shortening in cats: a comparison between two echocardiographic views.
11.35-11.50 ESVC-O-17 Cala Prevalence and clinical significance of heart murmurs in 809 cats
11.50-12.05 ESVC-O-18 Puccinelli The Vertebral Right Heart index: a new radiographic method to assess right heart enlargement in dogs 
12.05-12.20 ESVC-O-19 Grosso Echocardiographic reference intervals for right pulmonary artery dimension and distensibility index: a prospective study in 269 healthy dogs
12.20-12.35 ESVC-O-20 Mazzarella Feasibility of isomeric myography to measure vascular function in pet dogs
12.35-12.50 ESVC-O-21 Battaia Atrial depolarization waves localization and characterization on surface electrocardiogram in dogs with fast supraventricular tachycardias
14.25-14.40 ESVC-O-22 Oricco Association between echocardiographic indexes and urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) in dogs with myxomatous mitral valve disease
14.40-14.55 ESVC-O-23 Olsen Effect of the sodium-glucose cotransporter-2 inhibitor dapagliflozin on platelet aggregation response in Cavalier King Charles Spaniels with and without cardiac disease
14.55-15.10 ESVC-O-24 Olsen Inhibitory effect of the active pimobendan metabolite UDCG 212 on platelet aggregation in Cavalier King Charles Spaniels
SCH – Society of Comparative Hepatology 
Click here to read the speakers bio
Thursday 1 September
09.15-09.30 SCH-O-1 Nivy Copper-associated chronic hepatitis in Cavalier King Charles Spaniels 
09.30-09.45 SCH-O-2 Rodriguez-Cobos Clinical findings, bacteria implicated and antimicrobial resistance in 28 dogs with bacterial cholangitis in Spain: a multicentric retrospective study.  
09.45-10.00 SCH-O-3 Duperrier-Simond Prevalence and clinical relevance of cholelithiasis in cats: a multicentric retrospective study
10.00-10.15 SCH-O-4 Devriendt Does type and amount of food influence postprandial serum bile acid concentrations in healthy dogs?
10.15-10.30 SCH-O-5 Habermaass Serum liposoluble vitamins in canine cholestatic liver disease 
ESVCP – European Society of Veterinary Clinical Pathology
Click here to read the speakers bio
Thursday 1 September
14.25-14.40 ESVCP-O-1 Aroch Association between the red blood cell distribution width (rdw) at presentation in critically ill dogs and additional hematological analytes and survival
14.40-14.55 ESVCP-O-2 Rompf Kinetics of procalcitonin plasma concentrations in dogs with bacterial sepsis 
14.55-15.10 ESVCP-O-3 Thalmeier Cat alpha-1-acid glycoprotein enzyme-linked immunosorbent assay: population-based reference values and assay performance          
15.25-15.40 ESVCP-O-5 Majercikova Diagnostic value of cerebrospinal fluid analysis in epileptic cats with negative magnetic resonance imaging or hippocampal changes only
15.40-15.55 ESVCP-O-6 Henry Prevalence of neoplasia in dogs and cats with hypercobalaminemia: a retrospective case control study. 
ESVNU – European Society of Veterinary Nephrology and Urology
Click here to read the speakers bio
Thursday 1 September
09.00-09.15 ESVNU-O-1 Bar Nathan Long-term outcome of dogs recovering from acute kidney injury: 132 cases (2015-2021)
09.15-09.30 ESVNU-O-2 Geddes Calcium-phosphate metabolism in normocalcaemic non-pedigree cats with upper urinary tract stones
09.30-09.45 ESVNU-O-3 Palizzotto Cats with amyloid-A amyloidosis and urinalysis: proteinuria, electrophoresis and biomarker discovery
09.45-10.00 ESVNU-O-4 Weinekötter Tissue S100/calgranulin expression and blood neutrophil-to-lymphocyte ratios in urothelial carcinoma in dogs
10.00-10.15 ESVNU-O-5 Viitanen Follicular cystitis in dogs – Role of intramural E.coli bacteria
10.15-10.30 ESVNU-O-6 Reyes-Hughes Owner’s experiences of caring for a cat with chronic kidney disease (CKD) in the United Kingdom
Friday 2 September
09.00-09.15 ESVNU-O-7 Lippi Essential and non-essential serum amino acids in dogs at different stages of chronic kidney disease
09.15-09.30 ESVNU-O-8 Ioannou Retrospective evaluation of 22 dogs with leptospirosis requiring intermittent hemodialysis (2018-2021)
09.30-09.45 ESVNU-O-9 Rixon Neutrophil gelatinase-associated lipocalin and symmetric dimethylarginine in dogs with carcinoma or sarcoma
09.45-10.00 ESVNU-O-10 Tang A cross-sectional study assessing macroscopic nephrocalcinosis using ultrasonography in cats with chronic kidney disease
10.00-10.15 ESVNU-O-11 Chan Does the iodinated contrast agent administered to dogs during computed tomography imaging reduce the sensitivity of detecting a urinary tract infection?
10.15-10.30 ESVNU-O-12 Cuq Urine gamma-glutamyl transferase to creatinine ratio in dogs undergoing contrast-enhanced computed-tomography examination – a pilot study
11.20-11.35 ESVNU-O-13 Fortuna A retrospective analysis of risk factors for thrombotic disease in dogs with protein losing nephropathy
11.35-11.50 ESVNU-O-14 Tegner Comparison between the glomerular filtration markers symmetric dimethylarginine and creatinine in serum from 458 cats 
11.50-12.05 ESVNU-O-15 Mortier Urinary protein: creatinine ratio and urine specific gravity in cats: cystocentesis versus home sampling  
ESCG – European Society of Comparative Gastroenterology
Click here to read the speakers bio
Friday 2 September
09.00-09.15 ESCG-O-1 Ishii Dogs with chronic enteropathy have increased intestinal permeability
09.15-09.30 ESCG-O-2 Reisinger Evaluation of intestinal permeability, NetF toxin genes, sepsis and albumin in dogs with acute haemorrhagic diarrhoea syndrome
09.30-09.45 ESCG-O-3 Heilmann Serum transcobalamin analysis in dogs – method validation and association with serum cobalamin status in dogs with chronic enteropathy
09.45-10.00 ESCG-O-4 Blatt Hypocobalaminemia in dogs with parvovirus enteritis
10.00-10.15 ESCG-O-5 Lotti Investigation of the relationship of mucosa-associated bacteria to clinical and histological findings in dogs with protein losing enteropathy (PLE)
10.15-10.30 ESCG-O-6 Lotti A survey-based observational study on diagnostic and therapeutic approach to canine idiopathic protein-losing enteropathy: general practitioners’ versus gastroenterologists’ point of view
11.20-11.35 ESCG-O-7 Santos The impact of diet reassessment in the medical management of Refractory Chronic Enteropathy in dogs- A retrospective multicentric study
11.35-11.50 ESCG-O-8 Stübing The effect of metronidazole versus a synbiotic on selected intestinal bacteria and clinical improvement in dogs with acute diarrhoea 
11.50-12.05 ESCG-O-9 Cueni Course of disease in dogs hospitalized for acute pancreatitis – correlation of lipase activity (Roche colorimetric lipase assay, LIPC), pancreatic lipase immunoreactivity (PLI, measured as Spec PL) and clinical variables over time. 
12.05-12.20 ESCG-O-10 Kuzi The clinical course and the utility of a clinical severity scoring system and 1,2-o-dilauryl-rac-glycero glutaric acid-(6’-methylresorufin)-ester-lipase for monitoring of dogs with chronic pancreatitis
12.20-12.35 ESCG-O-11 Karra Fecal acute phase proteins as biomarkers in cats with chronic enteropathies 
12.35-12.50 ESCG-O-12 Remmel Long-term follow-up in a cohort of 97 cats diagnosed with low-grade intestinal T-cell lymphoma or lymphoplasmacytic enteritis: clinical, biological and therapeutic features.
ESVIM – European Society of Veterinary Internal Medicine 
Click here to read the speakers bio
Friday 2 September
08.00-08.15 ESVIM-O-1 Scott-Baumann Metabolomic approaches highlight biochemical pathways altered in hypertensive cats 
08.15-08.30 ESVIM-O-2 Suciu Trapped Neutrophil Syndrome in Border Collies: Clinical Presentation, Diagnostic Findings, Treatment and Outcome in 10 dogs within the UK and USA
08.30-08.45 ESVIM-O-3 Pichard Outcome and predictive factors for response to treatment of idiopathic immune-mediated polyarthritis in dogs: A retrospective study
09.00-09.15 ESVIM-O-4 Snoeck Serum 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D in dogs with sinonasal aspergillosis
09.15-09.30 ESVIM-O-5 Prior Sinonasal Aspergillosis in dogs: a retrospective review of diagnostic findings in multiple UK referral centres (2011-2021)
09.30-09.45 ESVIM-O-6 Prior Sinonasal Aspergillosis in dogs: a retrospective study of treatment and outcome in multiple UK referral centres (2011-2021) 
09.45-10.00 ESVIM-O-7 Champetier Nasopharyngeal stenosis in cats : a retrospective study of 21 cases comparing endoscopic and surgical treatment (2018-2022)
10.00-10.15 ESVIM-O-8 Lee-Fowler Evaluation of thermophysiological characteristics of brachycephalic obstructive airway syndrome utilizing the combination of a cold stimulus and infrared thermography.
10.15-10.30 ESVIM-O-9 Grobman Evaluation of Infrared Thermography and 6 Minute Walk Tests to Assess Thermoregulation and Exercise Intolerance in Dogs with Brachycephalic Obstructive Airway Syndrome 
11.05-11.20 ESVIM-O-10 Rizzoli Expression of Fibroblast Activation Protein in lungs of dogs with idiopathic pulmonary fibrosis and dogs with lung cancer
11.20-11.35 ESVIM-O-11 Lyssens Bronchiectasis, dynamic bronchomalacia and bronchiectasis/bronchomalacia syndrome in dogs: a retrospective study  
11.35-11.50 ESVIM-O-12 Canonne Seropositivity for Aspergillus and House Dust Mites antigens in dogs with eosinophilic bronchopneumopathy
11.50-12.05 ESVIM-O-13 Chan Prospective evaluation of the efficacy of inhaled steroids administered via the AeroDawg spacing chamber in management of dogs with chronic cough
12.05-12.20 ESVIM-O-14 Hartung Allergy testing in cats with feline lower airway disease
12.20-12.35 ESVIM-O-15 Gareis Correlation of radiographic and clinical parameters in cats with feline lower airway disease
12.35-12.50 ESVIM-O-16 Preibisz Utility of ultrasound-guided fine needle aspiration of non-circumscribed pulmonary lesions in dogs and cats.
ISCAID - International Society for Companion Animal Infectious Diseases
Click here to read the speakers bio
Saturday 3 September
08.45-09.00 ISCAID-O-1 Spiri Fecal Feline Coronavirus Shedding and Spike Gene Mutations in Cats with Feline Infectious Peritonitis Treated with GS-441524
09.00-09.15 ISCAID-O-2 Green A case series of 25 cats with effusive and non-effusive feline infectious peritonitis treated with a combination of remdesivir and GS-441524
09.15-09.30 ISCAID-O-3 Giselbrecht Prevalence of different outcomes of feline leukemia virus infection in four European countries
09.30-09.45 ISCAID-O-4 Rehme Feline panleukopenia outbreaks and risk factors in cats in animal shelters 
09.45-10.00 ISCAID-O-5 Bogedale Presence of potential enteropathogens and their association with diarrhoea in multi-cat households 
10.00-10.15 ISCAID-O-6 Domingues Case control study into acute diarrhoea in dogs potentially caused by Providensia alcalifaciens
10.15-10.30 ISCAID-O-7 Museux A series of 46 cases of Corynebacterium ulcerans infections in pets in France
11.20-11.35 ISCAID-O-8 Bello Serological prevalence and criteria for selection of dogs for screening of vector borne diseases using a point-of-care test in a referral population in the United Kingdom – multicentre retrospective study (2015 – 2020)
11.35-11.50 ISCAID-O-9 Jaffey Immunologic factors in dogs with pulmonary and disseminated coccidioidomycosis: a pilot study
11.50-12.05 ISCAID-O-10 Wright The impact of a short, animated film on owner attitudes towards antimicrobial use in companion animals – a randomised controlled trial
ESVONC – European Society of Veterinary Oncology
Click here to read the speakers bio
Friday 2 September
10.00-10.15 ESVONC-O-1 Marconato Subcutaneous mast cell tumors revisited: a prospective clinical study on 50 dogs
10.15-10.30 ESVONC-O-2 Guerra High sensitivity and negative predictive value of methylene blue as a single technique to rule out sentinel lymph nodes: a prospective study on 25 dogs with low-grade cutaneous mast cell tumors
11.20-11.35 ESVONC-O-3 Chalfon Patterns of nodal metastases, biological behaviour and prognosis of canine mast cell tumours of the pinnae: a multi-institutional retrospective study
11.35-11.50 ESVONC-O-4 Ubiali A retrospective study on bone metastasis in dogs with advanced-stage solid cancers
11.50-12.05 ESVONC-O-5 Faroni Timely adjuvant chemotherapy improves outcome in dogs with non-metastatic splenic hemangiosarcoma undergoing splenectomy
12.05-12.20 ESVONC-O-6 Agnoli benefit for capecitabine in dogs with biologically aggressive carcinoma of various origin: a single institution experience
12.20-12.35 ESVONC-O-7 Lopes Transcriptomic analysis of canine B and T cell lymphoma identifies differential gene expression
12.35-12.50 ESVONC-O-8 Børresen Experiences from the first ten canine oral cancer patients treated with FLASH radiotherapy
ESVE – European Society of Veterinary Endocrinology
Click here to read the speakers bio
Saturday 3 September
14.25-14.40 ESVE-O-1 van den Berg Whole transcriptome analysis of canine pheochromocytoma and paraganglioma
14.40-14.55 ESVE-O-2 Dias Plasma and Urinary Metanephrine and Normetanephrine in Healthy Cats – a Pilot Study 
14.55-15.10 ESVE-O-3 Kurtz Correlation between plasma renin activity determined by the traditional angiotensin I formation method and by a novel renin-angiotensin-system marker 
15.10-15.25 ESVE-O-4 Calvo Retrospective multicentre study of the medical and surgical management of feline primary hyperaldosteronism
15.25-15.40 ESVE-O-5 Kurtz Prospective evaluation of the telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats
15.40-15.55 ESVE-O-6 Sieber-Ruckstuhl Clinical features and long-term management with DOCP and prednisolone of cats with primary hypoadrenocorticism
15.55-16.10 ESVE-O-7 Sanders Canine pituitary organoids and tumoroids as 3D in vitro model for pituitary-dependent hypercortisolism
16.30-16.45 ESVE-O-8 Tardo Monitoring of diabetes mellitus with Flash glucose monitoring system: the owners’ point of view
16.45-17.00 ESVE-O-9 Eiermann Accuracy of a flash glucose monitoring system for cats with diabetic ketosis or ketoacidosis
17.00-17.15 ESVE-O-10 Falcone A mutation in the KCNJ11 gene and diabetes mellitus in the Labrador retriever 
17.15-17.30 ESVE-O-11 Niessen Once daily oral therapy for feline diabetes mellitus: SGLT-2-inhibitor velagliflozin as stand-alone therapy compared to insulin injection therapy in diabetic cats
17.30-17.45 ESVE-O-12 Lombardo Histological investigation of the endocrine pancreas in non-diabetic cats and its relationship with pancreatitis
17.45-18.00 ESVE-O-13 Thalmeier Assessment of the effect of inflammation on the quality of glycaemic control, insulin sensitivity and β-cell function in diabetic cats
ESVCN – European Society of Veterinary Comparative  Nutrition
Click here to read the speakers bio
Saturday 3 September
09.15-09.30 ESVCN-O-1 Carciofi Body composition and energy expenditure of obese dogs on weight loss programs fed diets with different amino acid profiles
09.30-09.45 ESVCN-O-2 Van Vertloo Development of a Diet-Induced Dyslipidemia Model in Healthy Dogs Fed a Westernized Diet
09.45-10.00 ESVCN-O-3 Cavalieri Carciofi The effect of starch to protein ratio in energy expenditure, body composition, and physical activity are different in neutered and intact, non-obese male cats
10.00-10.15 ESVCN-O-4 Söder Effects of physical exercise in dogs and dog owners – assessed quality of life, body condition score and body mass index 
10.15-10.30 ESVCN-O-5 Carciofi  Starch to protein ratio and moisture content of the food influence water balance and urine supersaturation for calcium oxalate and struvite in cats.